Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-03-15
- Target Recruit Count
- 96
- Registration Number
- NCT06259058
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT06238843
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 123
- Registration Number
- NCT06219941
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX
- Conditions
- Interventions
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Changhai Hospital
- Target Recruit Count
- 134
- Registration Number
- NCT06210360
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT06197438
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Target Recruit Count
- 490
- Registration Number
- NCT06194734
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: CarboplatinDrug: CisplatinProcedure: Computed TomographyDrug: CyclophosphamideBiological: DinutuximabDrug: DoxorubicinDrug: EtoposideProcedure: FDG-Positron Emission Tomography and Computed Tomography ScanProcedure: Hematopoietic Cell TransplantationDrug: IrinotecanDrug: IsotretinoinProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingDrug: MelphalanRadiation: Radiation TherapyProcedure: Radionuclide ImagingOther: Survey AdministrationDrug: TemozolomideDrug: ThiotepaDrug: TopotecanProcedure: Tumor ResectionDrug: Vincristine
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 478
- Registration Number
- NCT06172296
- Locations
- 🇺🇸
Blank Children's Hospital, Des Moines, Iowa, United States
🇺🇸Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients
- Conditions
- Interventions
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 50
- Registration Number
- NCT06169202
- Locations
- 🇨🇳
First Hospital of China Medical University, Shenyang, Liaoning, China
Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT06166589
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Target Recruit Count
- 186
- Registration Number
- NCT06139211
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.